UA99259C2 - Treating obesity with muscarinic receptor m1 antagonists - Google Patents

Treating obesity with muscarinic receptor m1 antagonists

Info

Publication number
UA99259C2
UA99259C2 UAA200900269A UAA200900269A UA99259C2 UA 99259 C2 UA99259 C2 UA 99259C2 UA A200900269 A UAA200900269 A UA A200900269A UA A200900269 A UAA200900269 A UA A200900269A UA 99259 C2 UA99259 C2 UA 99259C2
Authority
UA
Ukraine
Prior art keywords
mantagonist
acetylcholine receptor
muscarinic acetylcholine
treating obesity
antagonists
Prior art date
Application number
UAA200900269A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Брайан СИД
Джордан Мечаник
Original Assignee
Теракос, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Теракос, Инк. filed Critical Теракос, Инк.
Publication of UA99259C2 publication Critical patent/UA99259C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The preferential muscarinic acetylcholine receptor Mantagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.
UAA200900269A 2006-06-16 2007-06-15 Treating obesity with muscarinic receptor m1 antagonists UA99259C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80506606P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
UA99259C2 true UA99259C2 (en) 2012-08-10

Family

ID=40829458

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200900269A UA99259C2 (en) 2006-06-16 2007-06-15 Treating obesity with muscarinic receptor m1 antagonists
UAA200900268A UA98938C2 (en) 2006-06-16 2007-06-15 Treating psychological conditions using muscarinic receptor m1 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200900268A UA98938C2 (en) 2006-06-16 2007-06-15 Treating psychological conditions using muscarinic receptor m1 antagonists

Country Status (2)

Country Link
CN (2) CN101472476B (en)
UA (2) UA99259C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
DK2632468T3 (en) * 2010-10-25 2018-02-12 Univ Manitoba THERAPEUTIC COMPOSITIONS FOR SYMMETRIC DIABETIC POLYNEuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
WO2002022579A2 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
EP1369129A4 (en) * 2001-03-14 2005-08-03 Ono Pharmaceutical Co Remedies for depression containing ep1 antagonist as the active ingredient
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
BRPI0506807A (en) * 2004-04-22 2007-05-29 Mor Research Applic Ltd food consumption management method and pharmacological composition

Also Published As

Publication number Publication date
CN101472571A (en) 2009-07-01
CN101472476A (en) 2009-07-01
CN101472476B (en) 2013-10-30
UA98938C2 (en) 2012-07-10
CN101472571B (en) 2012-11-14

Similar Documents

Publication Publication Date Title
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
EP2056818A4 (en) Compositions and methods for neuroprotection
MX2010002781A (en) Novel combination of therapeutic agents.
WO2008024485A3 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
EP2032127A4 (en) Treating psychological conditions using muscarinic receptor m1 antagonists
WO2007098113A3 (en) Ccr3 inhibition for ocular angiogenesis and macular degeneration
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
UA94909C2 (en) Pharmaceutical composition of a neuroactive steroid and use thereof
WO2007121483A3 (en) Pre-mixed, ready-to-use iv bolus compositions and methods of use
BRPI0510170B8 (en) compound, pharmaceutical composition for the treatment of diseases mediated by the muscarinic acetylcholine receptor and use of the compound
WO2006055752A3 (en) INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2006135638A3 (en) Tanaproget compositions containing ethinyl estradiol
WO2006058059A3 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
WO2009140642A3 (en) Tricyclic antagonists of prostaglandin d2 receptors
WO2006065722A3 (en) Compositions and methods for pulmonary conditions
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
NZ588913A (en) Liver cancer drug
MY184864A (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
CL2007003266A1 (en) COMPOUNDS DERIVED FROM PROGESTERONA, ANTAGONISTS OF THE PROGESTERONE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF ENDOMETRIOSIS, MYOMAS OR TUMORS DEPENDENT ON HORMONES.